When was Neurovance founded?

Neurovance was founded in 2011 and raised its 1st funding round 1 year after it was founded.

Where is Neurovance located?

Neurovance is headquartered in Cambridge, United States.

Who is the current CEO of Neurovance?

Anthony McKinney of Neurovance.

How many employees does Neurovance have?

As of Dec 31, 2016, Neurovance has 7 employees, reflecting a 40% year-over-year growth in headcount.

Is Neurovance a funded company?

Neurovance is a funded company, having raised a total of $53M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 30, 2012.

When was the latest funding round of Neurovance?

Neurovance's latest funding was a $***** Series B round on Jan 04, 2017, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.67B in funding in 2026 to date.

Where does Neurovance rank among its competitors?

Neurovance ranks 9th amongst 98 active competitors, of which 21 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was HMNC Brain Health, which secured $50M in Jun, 2026.

Who are the top competitors of Neurovance?

Neurovance's top competitors include Alto Neuroscience, Enveda and Vanda Pharmaceuticals. Among them, HMNC Brain Health secured the most recent funding round in June, 2026.

Neurovance - 2026 Company Profile, Team, Funding & Competitors

Q: Is Neurovance an acquired company?

Neurovance got acquired by Otsuka on Mar 02, 2017.

Company Details

Neurovance is a clinical stage neuroscience-focused company. Following the development of centanafadine (formerly EB-1020) for adult Attention Deficit Hyperactivity Disorder (ADHD), the company is developing EB-1020 SR for adolescent & pediatric ADHD. Centanafadine (CTN) is a novel triple reuptake inhibitor that modulates norepinephrine, dopamine and, to a lesser extent, serotonin reuptake in a ratio of 1:6:14, respectively to improve focus, attention and executive function.

Key Metrics

Founded Year

2011

Location

Cambridge, United States

Stage

Acquired

Total Funding

$53M in 6 rounds

Latest Funding Round

Series B, Jan 04, 2017, $*****

Investors

Venture Investors & 4 more

Ranked

9^th among 98 active competitors

Employee Count

7 as on Dec 31, 2016

Similar Companies

Alto Neuroscience & 126 more

Exit Details

Acquired by Otsuka (Mar 02, 2017)

View Neurovance's full profile

Neurovance got acquired by Otsuka on Mar 02, 2017 at an acquisition amount of $*****.

Click here to take a look at Neurovance's acquisition in detail

Neurovance has raised a total funding of $53M over 6 rounds. Its first funding round was on May 30, 2012. Neurovance has 5 institutional investors.

Here is the list of recent funding rounds of Neurovance:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 04, 2017	7113556	Series B	4057223	6871939	4429067	6121359
Dec 01, 2016	2817368	Series B	2223913	1353655	7529227	9677877
Jun 29, 2015	2480515	Series B	9946491	4250220	6082766	9299180

Access funding benchmarks and valuations. Sign up today!

View details of Neurovance's funding rounds and investors

The founders of Neurovance is Anthony McKinney.

Here are the details of Neurovance's key team members:

Anthony McKinney: President, CEO and Co-Founder of Neurovance and founder of 1 other company.

View details of Neurovance's Founder profiles and Board Members

Neurovance's employee count trend

Neurovance has 7 employees as of Dec 16. The total employee count is 40.0% more than what it was in Dec 15. Here is Neurovance's employee count trend over the years:

Uncover Neurovance's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neurovance include Alto Neuroscience, Enveda and Vanda Pharmaceuticals. Here is the list of Top 10 competitors of Neurovance, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alto Neuroscience 2019, San Francisco (United States), Public	AI-driven drug discovery platform for neurological diseases based on patients biomarkers	$145M	Commodore Capital, Alpha Wave Global & 36 others	68/100
2nd	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Premji Invest, Kinnevik & 30 others	63/100
3rd	Vanda Pharmaceuticals 2003, Washington, DC (United States), Public	Developer of pharmaceutical products for treating CNS disorders	$33.5M	Domain Associates, MedImmune Ventures & 4 others	62/100
4th	Beckley Psytech 2019, Oxford (United Kingdom), Series B	Developer of rapid-acting psychedelic medicines for mental health disorders	$153M	ATAI, Bain Capital & 28 others	62/100
5th	Seaport Therapeutics 2020, Boston (United States), Public	Developer of therapeutics to treat neuropsychiatric disorders	$325M	T. Rowe Price, Foresite Capital & 7 others	60/100
6th	Supernus Pharmaceuticals 2005, Rockville (United States), Public	Innovating CNS treatments, improving lives through neurological and psychiatric solutions	-	Abingworth, Westwicke & 6 others	59/100
7th	HMNC Brain Health 2010, Munich (Germany), Series B	Developer of targeted therapies for depression and other neuropsychiatric disorders	$41.5M	Maschmeyer Group, The Jahr Group & 10 others	55/100
8th	Reunion Neuroscience 2022, Toronto (Canada), Acquired	Developer of therapeutics for mental health conditions	$120M	MPM BioImpact, Novo Holdings & 7 others	54/100
9th	Neurovance 2011, Cambridge (United States), Acquired	Drug to modulate neurochemicals to treat Attention Deficit Hyperactivity Disorder .	$53M	Tekla Capital Management, GBS & 3 others	53/100
10th	Reviva Pharmaceuticals 2006, San Jose (United States), Public	Develops therapeutic drugs for treatment of central nervous system	$49.1M	Lynx Financial	53/100